We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Tiffany
Patterson
tiffanypatterson05@gmail.com
Dr
Harriet
Hurrell
h.e.l.hurrell@doctors.org.uk
Other forms of heart disease
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Severe aortic stenosis carries an extremely poor prognosis, with 50% mortality at two years. Trans-catheter aortic valve implantation (TAVI) has become an important alternative to surgical aortic valve replacement and shown to be superior in terms of early clinical outcomes for those at high, intermediate and more recently, low surgical risk. However, little is known about durability and recent concerns have been raised regarding detection of subclinical valve leaflet thrombosis and reduced leaflet mobility in the region of 15%. TAVI thrombosis has been reported to lead to early valve failure and increased incidence of thromboembolic stroke. Limited evidence exists in regard to use of anti-thrombotic therapies post TAVI, with recent data suggesting harm with oral anticoagulation in the absence of atrial fibrillation. TAVI leaflet thrombosis is likely secondary to leaflet characteristics, turbulent flow and pro-thrombotic state. However, we have no indication as to which patients are at greater risk. The aim of this project is twofold. First, we will compare haemostatic, structural and clinical characteristics of patients with TAVI thrombosis to a matched control cohort without thrombosis. Secondly, to identify a biomarker screening tool for valve thrombosis by performing a pre-procedure clotting screen in this cohort. This will enable identification of this at-risk cohort to tailor anti-thrombotic therapies.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
-Known haematological disorder -Active malignancy Two cohorts identified at follow up: Elevated mean gradient > 10mmHg (group of interest), no elevated mean gradient (control)
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by King's College London and funded by BRITISH MEDICAL ASSOCIATION SCHOLARSHIP TRUST FUND .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 47648
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
